High-density lipoprotein cholesterol (HDL-C) has been suggested to be associated with breast cancer. However, the roles of HDL-C and hypertriglyceridemia on breast cancer still have been controversial. The goal of this study was to investigate the association between HDL-C with breast cancer risk, stratifying by menopausal status, and body mass index. The hormonal receptor status of breast has been proposed to modify the effect of HDL-C on breast cancer. Multicenter hospital-based case-control study was conducted from November 2004 to December 2005 in Korea. After one to two individual matchings by age (F5 years) and menopausal status, 690 cases and 1,380 controls were included in the analysis. Odds ratios (OR) and 95% confidence intervals (95% CI) were estimated by conditional, unconditional, and multinomial logistic regressions. Protective effect of HDL-C on breast cancer was only observed among premenopausal women with an OR (95% CI) of 0.49 (0.33-0.72) for HDL-C z60 versus <50 mg/dL (P trend < 0.01). Only nonobese premenopausal women had a significant decreased risk (OR, 0.34; 95% CI, 0.22-0.53). OR (95% CI) of low HDL-C (<50 mg/dL) and high triglyceride (TG; z150 mg/dL) category was 2.20 (1.32-3.67) on estrogen receptor-negative and progesterone receptor-negative breast cancer compared with high HDL-C (z50 mg/dL) and low TG (<150 mg/dL) category. This study suggests that higher level of HDL-C may reduce breast cancer risk among premenopausal women. Estrogen receptor-negative and progesterone receptor-negative breast cancer was associated with dyslipidemia, which implicates that association among HDL-C, TG, and breast cancer may be modified by receptor status. (Cancer Epidemiol Biomarkers Prev 2009;18(2):508 -15) 
Introduction
Breast cancer is the most commonly occurring cancer with 1,151,300 incident cases recorded worldwide in 2002 (1) . Geographic incidences vary by 4-to 15-fold, with highest rates in Europe and North America (age-adjusted incidence rate, 97-145 per 100,000) and lowest rates in Asia (except Japan; age-adjusted incidence rate, 18-25 per 100,000) and Africa (age-adjusted incidence rate, 10-25 per 100,000; ref. 1). Although western countries have reported higher rates of breast cancer incidence and mortality, changes in the incidence of breast cancer are most dramatic in Asia (2) . In fact, remarkable changes in breast cancer mortality rates are being reported over the last 20 years in Korea (2) . Epidemiologic studies indicate that lifestyle factors related to westernization are associated with increases in breast cancer incidence in Asian countries, which may be explained by higher animal fat consumption, lower levels of physical activity, obesity, early menarche, and changing reproductive profiles, that is, fewer full-term pregnancies and increased age at the first full-term pregnancy (3, 4) .
Obesity is a well-known risk factor for postmenopausal breast cancer irrespective of race or country (5, 6) . The increased risk in postmenopausal women is explained possibly due to increased level of circulating estradiol and reduced level of sex hormone-binding globulin by the conversion of androgens to estrone in adipose tissue (5, 7) . The relationship between obesity and premenopausal breast cancer is known to be an inverse association or nonassociation, but the results are inconsistent among studies (8) (9) (10) (11) . Possible mechanisms of the inverse association can be explained by obesity accompanying anovulatory and irregular cycles, which means reduced exposure of estrogen or a reduction in serum progesterone levels (11) .
A variety of endocrine changes are associated with obesity, which is increase in leptin, insulin, insulin-like growth factor-I, androgens, and progesterone (5, 12) .
Obesity also influences lipid profile and inversely associates with plasma high-density lipoprotein cholesterol (HDL-C; refs. 13, 14) . Obesity and HDL-C are components of metabolic syndrome, which is characterized by the four factors: abdominal obesity, dyslipidemia (low HDL-C and hypertriglyceridemia), glucose intolerance, and hypertension. Several studies have suggested that high insulin might be causally linked to breast cancer and that higher insulin-like growth factor-I levels may predict the development of breast cancer (15) (16) (17) (18) (19) . However, the roles of HDL-C and hypertriglyceridemia on breast cancer risk are unclear (20, 21) .
Moreover, hormonal receptor of breast cancer has been proposed to modify the effect of HDL-C on breast cancer, but the results to date are inconsistent (20, (22) (23) (24) . It was found that HDL-C stimulates the proliferation of hormone-dependent and hormone-independent mammary tumor cell lines, but hormone-independent cells showed highest response (22) . However, it has been suggested that lipophilic statins have a growth inhibition effect of breast cancer, which is more sensitive in estrogen receptor (ER)-negative cases (23) .
Here, we aimed to observe the association between HDL-C levels and breast cancer risk in Korean women. The combined effect of HDL-C and triglyceride (TG) was also examined to evaluate the relationship between dyslipidemia and breast cancer risk. We measured the risk stratified by menopausal status and body mass index (BMI). In addition, we examined the association between HDL-C and breast cancer according to hormone receptor status of cancer. To achieve these goals, a hospital-based case-control study was conducted, and serum lipid levels were analyzed.
Materials and Methods
Study Population. We designed a hospital-based casecontrol study to evaluate risk factors and genetic polymorphism with breast cancer in Korean women. Cases were recruited from two teaching hospitals in Seoul from November 2004 to December 2005. Inclusion criteria of the case group were admitted for the (a) treatment of incident breast cancer, (b) signed written consent and agreement to participate in this study, and (c) completion of a questionnaire. All of the cases were newly and histologically diagnosed with invasive ductal or lobular carcinoma of breast. Among 1,453 number of source population of cases, 1,085 (74.7%) cases participated in the study.
The study controls were women who visited health examination centers in two other teaching hospitals in Seoul and Pyungchon. They visited the health examination center for a regular health checkup. Pyungchon is located 12 to 20 km far from Seoul and is a satellite city of Seoul with a similar environment of modernization. The controls were ages z35 years with no reported history of any cancer and agreed to participate offering a consent form; in total, 1,982 controls were recruited. After applying exclusion criteria, women ages <35 years, those not offering serum, and those with a history of any cancer, amenorrhea, hysterectomy, or oophorectomy, cases and controls were individually matched 1:2 by age (F5 years) and menopausal status. Finally, the study population consisted of 690 cases and 1,380 controls. Data Collection. Participants were interviewed using a standardized questionnaire by specially trained interviewers. Each interview took 35 to 45 min. Subjects provided demographic characteristics including education, medical history, and details of medication. In addition, family history of breast cancer among the firstand second-degree relatives, lifestyle factors (smoking, alcohol consumption, and exercise), hormone-related factors (age at menarche, menopausal status, age at menopause, hormone replacement status, and history of oral contraceptive use), and reproductive histories (age at the first full-term pregnancy, number of full-term pregnancies, and duration and the number of children breast-fed) were obtained. We grouped ''postmenopause'' as both natural (no menstruation in 12 months) and surgical menopause at baseline. Women who answered ''irregular period and almost no menstruation through last 12 months'' and ''no menstruation through last 3 months'' were also grouped as ''postmenopause.'' Height and weight were self-reported in the case group and directly measured in the control group. BMI was calculated as weight/height (kg/m 2 ) and subdivided into four categories: <18.5, 18.5 to 22.9, 23.0 to 24.9, and z25.0. Clinical information of breast cancer patients, that is, tumor size, lymph node involvement, and ER and progesterone receptor (PR) status, were collected through medical chart review. Hormonal status was categorized into four groups as combinations of ER and/or PR expression profiles for analysis: ER-/PR-, ER-/PR+, ER+/PR-, and ER+/PR+.
After completing interviews, 10 mL whole blood was sampled from each participants, and 4 to 5 mL blood was collected in EDTA tube to preserve serum. All subjects fasted at least 8 h before sampling. Blood samples were processed within 3 h and then stored at À70jC refrigerator. The study protocol was approved by the Institutional Review Board of Seoul National University Hospital.
The frozen serum samples were thawed and total cholesterol, HDL-C, and TG concentrations were measured using standard enzymatic methods by a Hitachi 7600 or a 7180 Biochemical Analyzer for both cases and controls. Lipid levels were analyzed in one designated laboratory during June 2006 in the case group and from November 2005 to January 2006 in the control group. Serum low-density lipoprotein cholesterol levels were estimated from serum total cholesterol, HDL-C, and TG levels using the Friedewald formula.
Statistical Analysis. To estimate odds ratios (OR) and 95% confidence intervals (95% CI) of serum lipid levels for breast cancer risk, both conditional and unconditional logistic regressions were used. Cutoff levels used for serum lipids were based on the Third Report of the National Cholesterol Education Program Expert Panel on the Detection, Evaluation, and Treatment of High Blood Cholesterol Adults (25) . Lipids were categorized into two or three groups: HDL-C as <50, 50 to 59, and z60 mg/dL and TG as <150 and z150 mg/dL. Combined variable of HDL-C and TG was grouped as ''HDL-C z 50 and TG < 150,'' ''either HDL-C < 50 or TG z 150,'' and ''HDL-C < 50 and TG z 150.'' Splitting the category in ''either low HDC-C or high TG'' into two categories (''low HDC-C and low TG'' and ''high HDC-C and high TG'') would be one way to inform whether they are independent predictors of increased breast cancer risk. However, sample size in ''HDL z 50 and TG z 150'' category was too small to interpret and each splitted group has lack of clinical implication, and we combined two categories to observe any trend through categories.
To evaluate the independent effects of HDL-C, age (continuous), family history of breast cancer (yes or no), age at menarche (V14, 15, 16, and z17 years), age at the first full-term pregnancy (nulliparity, 15-24, 25-29, and z30 years), and total cholesterol (continuous) were simultaneously adjusted in the multivariable model. To calculate the ORs by hormone receptor status of four categories, multinomial logistic regression was applied. Likelihood ratio statistics were used to assess the linear trends of ORs. SAS software version 9.1 (SAS Institute) was used for most of the statistical analysis, and Stata 8.0 (StataCorp) was used for multinomial logistic regression.
Results
Mean F SD age was similar between cases and controls, which was 48.8 F 8.6 for cases and 48.2 F 6.5 for controls (P = 0.09; Table 1 ). Women ages 40 years were more represented in controls (61% of controls and 46% of cases; P < 0.01). Education level did not differ between cases and controls (P = 0.15). Proportion of family history of breast cancer was higher in cases than in controls (6.1% and 0.9%, respectively; P < 0.01). For premenopausal women, mean BMI was 22.6 kg/m 2 in cases and 22.5 kg/m 2 in controls with no significant difference (P = 0.36). For postmenopausal women, mean BMI was 24.0 kg/m 2 in cases and 23.3 kg/m 2 in controls, which was statistically significant (P < 0.01). Postmenopausal women were 34.6% of all subjects. The proportion of nulliparous women was 8.6% for cases and 5.8% for controls (P = 0.02). Proportion of ER-cases was 34%, and it was 38% for PR-cancers. For the proportion of ER-/PR-cancers, ER-tumors were more common in postmenopausal (36.4%) than in premenopausal (32.4%) women (P m2 = 0.56), and PR-tumors were also common in postmenopausal women (30.2% in premenopausal women and 51.5% in postmenopausal women; P m2 < 0.01).
The association between HDL-C and breast cancer risk was stratified by menopausal status (Table 2) . Protective effect of HDL-C was determined only among premenopausal women; OR (95% CI) was 0.49 (0.33-0.72) for HDL-C z60 versus <50 mg/dL (P trend < 0.01). The combination of low HDL-C and high TG (HDL < 50 and TG z 150) increased breast cancer risk in premenopausal women (P trend = 0.04) compared with high HDL-C and low TG level (HDL z 50 and TG < 150).
OR of HDL-C and breast cancer risk was examined stratifying by menopausal status and BMI (Table 3) . For HDL-C, an inverse association between HDL-C and breast cancer was found only in the premenopausal group of BMI < 23.0 kg/m 2 . In the premenopausal group of BMI < 23.0 kg/m 2 , relative to HDL-C < 50 mg/dL category, the OR (95% CI) was 0.66 (0.43-1.00) for the middle category (50-59 mg/dL) and 0.34 (0.22-0.53) for the highest category (z60 mg/dL; P trend < 0.01). Among premenopausal women, interaction between HDL-C with the first and third categories (<50 and >60 mg/dL) and BMI (<23.0 and z23.0 kg/m 2 ) was significant (P = 0.05). For the combined variable of HDL-C and TG, lower HDL-C and higher TG increased breast cancer risk only in the group of BMI < 23.0 kg/m 2 in both premenopausal and postmenopausal women, but the trend was only significant among premenopausal women (premenopausal P trend < 0.01 and postmenopausal P trend = 0.07). Table 4 shows the effect of lipid level on breast cancer risk by ER and PR status. HDL-C was significantly inversely related with breast cancer risk regardless of the positivity of receptors. Category of low HDL-C and high TG showed increased risk of ER-cancers (''HDL < 50 and TG z 150'' versus ''HDL z 50 and TG < 150'': OR, 2.08; 95% CI, 1.30-3.35) and risk of PR-cases (OR, 2.17; 95% CI, 1.40-3.37).
We examined jointed receptor status of ER and PR; 189 (31.3%) were ER-/PR-, 44 (7.3%) were ER-/PR+, 70 (11.6%) were ER+/PR-, and 301 (49.8%) were ER+/PR+ (Table 5 ). An inverse association between breast cancer and HDL-C was observed in the ER-/PR-and ER+/PR+ subgroups. The risk was evident in ER-/PR-cases; OR (95% CI) of HDL z60 versus <50 mg/dL was 0.49 (0.32-0.76) in ER-/PR-group and 0.59 (0.41-0.85) in ER+/PR+ group. Low level of HDL-C (<50 mg/dL) and high level of TG (z150 mg/dL) increased risk of ER-/PRbreast cancers by 2.2-fold (OR, 2.20; 95% CI, 1.32-3.67) compared with ''HDL-C z 50 and TG < 150 (mg/dL)'' category.
Discussion A higher HDL-C level was associated with reduced risk of premenopausal breast cancer. HDL-C z 60 mg/dL decreased breast cancer risk by 0.49-fold (OR, 0.49; 95% CI, 0.33-0.72) compared with HDL-C < 50 mg/dL among premenopausal women. When it was stratified by BMI, however, only in the premenopausal group of BMI < 23.0 kg/m 2 was there significant inverse relationship between HDL-C and breast cancer risk (P trend < 0.01).
The association between HDL-C and breast cancer risk by menopausal status has been inconsistent among studies (13, (26) (27) (28) (29) (30) (31) (32) (33) . However, several results show consistent results of our study. In a recent cohort study of 359 cases among 7,575 members, low baseline HDL-C level showed an modest increase of breast cancer only among premenopausal women (hazard ratio, 1.67; 95% CI, 1.06-2.63; ref. 13) . In a nested case-control study (33) with 51 incident cases among 5,207 subjects, there was an inverse association between serum HDL-C and breast cancer. The risk was 0.3 (95% CI, 0.1-0.8) for women in the highest serum HDL-C quartile versus women in the lowest quartile. In addition, TG showed a positive association with breast cancer incidence, although this trend was marginal (P = 0.06). Increase of HDL-C level was a protective factor of breast cancer in another nested case-control study with 100 cases and 200 controls (26) .
There are evidences that metabolic imbalance in young women are associated with breast cancer. Increased levels of insulin-like growth factor-I in premenopausal young women has been suggested to be associated with the occurrence of subsequent postmenopausal breast cancer (19) . Insulin and insulin-like growth factor-I are positively correlated to obesity, and obesity is also associated with a lower HDL-C level. HDL-C, obesity, and premenopausal breast cancer in Korea may be related to westernization, which has been related to obesity and the activation of metabolic pathways in cancer. Westernization has been suggested to be a risk factor of some hormone-related cancers (e.g., breast, colon, prostate, and pancreatic cancers; ref. 34) . Immigrant studies have given evidences that westernized lifestyle increases the level of estrogen levels and results in a higher incidence of breast cancer (35) .
Obesity was associated with a lower HDL-C level in controls in this study, which is consistent with previous studies (36) . However, the inverse relationship between HDL-C and breast cancer risk was shown only in the nonobese premenopausal women. There can be several explanations for these results. First, we could not totally exclude a spurious effect. About 20% of BMI was missing among controls and the matching was broken. After stratifying into four groups, the power may have been reduced. Second, obesity in young age correlates with anovulary state, and simultaneously, hormonal change may accompany and obscure the true relationship of HDL-C and risk of breast cancer (12, 37). Furberg et al. (32) reported that the inverse relationship between HDL-C and breast cancer was only significant among obese (BMI z 25 kg/m 2 ) postmenopausal women from a cohort study conducted in Norway, which is incompatible with our result. The relatively small number of nonobese premenopausal may cause limited power in the study (32) . The result in our study among postmenopausal women should also be carefully interpreted, because the sample size was small after stratification.
Combined effect of HDL-C and TG was examined in our study, and we found that these criteria of dyslipidemia in metabolic syndrome are associated with breast cancer risk. In an appended analysis, OR (95% CI) for ''HDL-C < 50 and low TG < 50'' was 1.74 (1.15-2.63) and OR (95% CI) for ''HDL < 50 and TG z 150'' was 1.63 (0.90-2.96; data not shown), and we suggest that TG was also associated with breast cancer risk. A few studies have examined the relationship between dyslipidemia and breast cancer risk. Previous case-control studies have enrolled relatively small subject numbers. In an African American study with 58 cases and 105 controls, only TG was found to be positively associated with breast cancer (27) . Michalaki et al. reported higher total cholesterol/ HDL-C ratios in 56 breast cancer cases than in 44 controls NOTE: Unconditional logistic regression adjusted for age (continuous), family history of breast cancer (yes or no), age at menarche (V14, 15, 16, and z17 years), age at first full-term pregnancy (nulliparity, 15-24, 25-29, and z30 years), and total cholesterol (continuous). *Among premenopausal women, P interaction between HDL-C (with the first and the second) category and BMI was 0.08 and P interaction between HDL-C (with the first and the third) category and BMI was 0.05. cAmong postmenopausal women, P interaction between HDL-C (with the first and the second) category and BMI was 0.60 and P interaction between HDL-C (with the first and the third) category and BMI was 0.37. bP trend calculated with likelihood ratio test in a logistic regression model.
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(28). Ray and Husain reported that low-density lipoprotein cholesterol and TG levels were significantly increased and that HDL-C was significantly decreased in breast cancer cases (31) . It is known that HDL-C plays a key protective role against oxidative membrane damage, and alterations in lipid and apolipoprotein levels could contribute to cellular inflammation (38) . Decreased level of HDL-C and increased level of total cholesterol, low-density lipoprotein cholesterol, and TG have been related to increased level of proinflammatory cytokines, including tumor necrosis factor-a and interleukin-6 (39). Moreover, decreased level of HDL-C is associated with apolipoprotein A-I for acute inflammation and may be a sign of the possible development of chronic inflammation (40) . High low-density lipoprotein cholesterol levels result in higher levels of oxidized low-density lipoprotein cholesterol, which increases reactive oxygen species levels. Reactive oxygen species subsequently damage DNA, delay DNA repair, activate oncogenes, and inactivate tumor suppressor genes, which results in chronic inflammation. However, the pathogenesis of breast cancer by HDL-C is still not confirmed. The direct effect of HDL-C on sex hormone levels and vice versa is complex and also unclear (21) .
This study, to our knowledge, is the first epidemiologic study examining the association of lipid profiles and breast cancer risk by hormone receptor status. We observed that dyslipidemia was associated with ER-/PRbreast cancer, which is known to have poor prognosis. The relationship among HDL-C, hormonal status, and breast cancer still has controversies (22) (23) (24) (41) (42) (43) , but recently it was reported that ER-breast cancer cell lines were more sensitive to growth inhibition by lipophilic statins than ER+ cell lines (23, 43) . It was shown that statins can decrease tumor formation and inhibit metastasis from in vivo studies of mouse mammary tumor models (44) , and some researchers suggest that statin usage could be inversely associated with cancer (41, 45) . These in vitro and in vivo studies support the protective role of HDL-C in breast cancer, but the risk ratio of breast cancer with statins use was 1.01 (95% CI, 0.79-1.30) from a meta-analysis with seven trials (41) . In this present study, it is unable to completely rule out the possibility of by-chance effect because we stratified hormonal status by four groups and the number of cases was reduced in each stratum. We need more evidences from welldesigned epidemiologic studies, which reveal the association of serum lipids and breast cancer by hormonal receptor status in advance of randomized control studies (46) .
Lower levels of total cholesterol are found in cancer patients, and this is much more severe in advanced-stage disease. In this study, lower levels of total cholesterol were observed in larger and histologic advanced tumors; however, this was not significant. Regardless of whether cholesterol levels were measured before or after a diagnosis of breast cancer, the results of previous studies are inconsistent (20) .
Our study has several strengths. We enrolled a large number of premenopausal cases. In Korea, age groupspecific breast cancer incidence is the highest in the 45-to 49-year-old group and decreases as age increases, and this trend has been more definite in recent years (47) . Birth cohort effect is suggested to be contributed to this unique pattern, which can be explained by westernization and higher obesity. Our results indicate that HDL-C, which is related to energy balance, associate with premenopausal breast cancer in a rapidly westernization country. Another is that we observed the effect of dyslipidemia with a combination of HDL-C and TG on breast cancer. The other strength of our study is that we analyzed the association between HDL-C and breast cancer by ER and PR status, which gives us a clue of HDL-C as a marker with a different effect for a different type of hormonal receptor.
Hospital-based case-control designs have limitations in terms of evaluating associations between cancers and metabolites, because it is unable to completely rule out reverse causation due to potential disease effects before detecting the disease. To overcome this limitation, we examined average lipid serum levels with respect to tumor size, numbers of lymph node invaded, and histologic grade. After confirming that average levels were not statistically different between clinical stages, we also restricted our analysis to invasive breast cancer cases with tumor sizes <5 cm and found that risks were similar to those determined before restriction. However, we cannot rule out that the interaction observed by menopausal status may result from reverse causation due to the different clinical picture between menopausal status; that is, premenopausal breast cancers tend to be more aggressive and/or fast-growing, have short interval period, and due to different metabolic status at the time of diagnosis.
To minimize recall bias, data of our study were collected from a well-trained interviewer. To avoid selection bias, we recruited controls from women who visited hospitals for regular health checkups, and both cases and controls were enrolled from teaching hospitals. We excluded women with amenorrhea, hysterectomy, and oophorectomy before matching to decrease the imbalance of long-term estrogen exposure between subjects, and this may decrease external validity but increase internal validity. Weight and height were informed by different methods between groups, which may cause differential bias. Previous studies suggest trends of underreporting for weight and BMI and overreporting for height. However, there is a report from the Third National Health and Nutrition Examination Survey of the United States that self-reported heights and weights can be used for younger adults and have limitations for older adults ages z60 years (48) . Moreover, only the case group self-reported their BMI, and if under-reporting happened, it can lead to null association. Cancer patients may lose body weight, and reverse causation effect may also lead to null association. However, mean BMI was higher in cases; moreover, the difference in BMI between groups was significant in postmenopausal women. Samples were analyzed with a time lag between groups and this can be a source of information bias. Although we have these limitations, any batch effects were minimized because samples were first thawed and analyzed in one laboratory (49) . Duration of storage was also different by groups, which can cause unstable measurements, but serum samples were stored at À70jC so that we can exclude many possibility of storage effects from temperature (50) .
In conclusion, our results support the hypothesis that lower serum HDL-C levels are associated with a higher risk of breast cancer among premenopausal women. This association was evident in nonobese premenopausal women and ER-/PR-breast cancers. These results warrant further researches to examine the interaction between HDL-C and endogenous hormone levels, exogenous hormone factors by menopausal status, and by hormonal receptor status on breast cancer risk.
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